Q3 2019 EPS Estimates for BioScrip Inc Reduced by Barrington Research (NASDAQ:BIOS)

BioScrip Inc (NASDAQ:BIOS) – Stock analysts at Barrington Research decreased their Q3 2019 EPS estimates for shares of BioScrip in a research report issued to clients and investors on Wednesday, July 31st. Barrington Research analyst M. Petusky now expects that the company will post earnings per share of ($0.06) for the quarter, down from their previous forecast of ($0.05). Barrington Research has a “Buy” rating and a $4.00 price objective on the stock. Barrington Research also issued estimates for BioScrip’s Q4 2019 earnings at ($0.02) EPS, FY2019 earnings at ($0.32) EPS and FY2020 earnings at ($0.17) EPS.

BioScrip (NASDAQ:BIOS) last released its quarterly earnings data on Tuesday, July 30th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.04). The firm had revenue of $191.52 million during the quarter, compared to analyst estimates of $185.73 million.

Several other equities research analysts also recently commented on the company. BidaskClub upgraded BioScrip from a “hold” rating to a “buy” rating in a report on Thursday, July 18th. Zacks Investment Research upgraded BioScrip from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a report on Thursday, June 20th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. BioScrip currently has a consensus rating of “Buy” and a consensus price target of $4.60.

Shares of NASDAQ:BIOS opened at $2.67 on Monday. The stock has a market cap of $352.66 million, a P/E ratio of -5.45 and a beta of 0.66. BioScrip has a one year low of $1.56 and a one year high of $4.14. The company’s 50-day moving average is $2.63.

Large investors have recently made changes to their positions in the stock. SG Americas Securities LLC purchased a new stake in shares of BioScrip during the 1st quarter valued at about $49,000. FNY Investment Advisers LLC increased its holdings in BioScrip by 840.9% during the 1st quarter. FNY Investment Advisers LLC now owns 25,000 shares of the company’s stock worth $50,000 after purchasing an additional 22,343 shares during the last quarter. BNP Paribas Arbitrage SA increased its holdings in BioScrip by 205.2% during the 1st quarter. BNP Paribas Arbitrage SA now owns 26,338 shares of the company’s stock worth $53,000 after purchasing an additional 17,709 shares during the last quarter. Marathon Capital Management increased its holdings in BioScrip by 9.9% during the 2nd quarter. Marathon Capital Management now owns 47,245 shares of the company’s stock worth $122,000 after purchasing an additional 4,250 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY increased its holdings in BioScrip by 383.3% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 45,013 shares of the company’s stock worth $161,000 after purchasing an additional 35,700 shares during the last quarter. Institutional investors and hedge funds own 78.55% of the company’s stock.

About BioScrip

BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.

Read More: Diversification For Individual Investors

Earnings History and Estimates for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.